Please assess the completion status of the following clinical trial:

Trial Title: Health Outcomes With CPAP or NIV in Patients With COPD and a Sleep Related Breathing Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consenting adults who have completed polysomnography at the University of Alberta Sleep Disorders Laboratory in Edmonton, Alberta, Canada.~* Naïve to CPAP or NIV therapy or have use of CPAP or NIV \<4 weeks in the past~* Diagnosed with COPD by a respirologist and has fixed airflow obstruction on spirometry (i.e., post-bronchodilator FEV1/FVC \<LLN on spirometry or FEV1/FVC \<0.70 if the LLN is not provided)~* Diagnosed with a SRBD for which CPAP or NIV are commonly prescribed, as defined below; some of the patients with mild SRBD or a SRBD suspected to be secondary to COPD rather than OSA (e.g. mild OSA, sustained hypercarbia, hypoxemia etc) may not be prescribed CPAP or NIV at the treating physician's discretion~  * OSA will be defined as a predominantly obstructive apnea-hypopnea index (AHI) ≥5 events/hr of sleep on sleep diagnostic testing in the presence of symptoms/relevant comorbidities or an AHI ≥15 events/hr irrespective of symptoms. If home sleep apnea testing was used in place of polysomnography, the respiratory event index (REI) will be a surrogate of AHI.~ * Hypoventilation will be defined by polysomnography criteria as a sustained elevation in the TcCO2 to be \>55 mmHg for ≥10 min or a rise in TcCO2 by \>10 mmHg to a value \>50 mmHg for ≥10 min. If an arterial blood gas is available, sustained hypercapnia as defined by arterial carbon dioxide oxygen tension (PaCO2) \>45 mmHg or serum bicarbonate (HCO3) ≥27 mmol/L while medically stable will be reported.~Exclusion Criteria:~* Significant lung disease in addition to COPD~* Neuromuscular disease including diaphragmatic paralysis~* Dementia~* Treatment with CPAP or NIV for \>4 weeks prior to study eligibility.~* Refusal to participate~* Inability to consent in English and do not have an interpreter readily available~* Current diagnosis of an active malignancy~* Central sleep apnea as the indication for PAP treatment. Central sleep apnea will be defined as a central hypopnea index ≥5 events/hr of sleep on polysomnography and the number of central apneas and/or central hypopneas is \>50% of the AHI with or without Cheyne-Stokes breathing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COPD and SRBD prescribed NIV or CPAP (Type: None): Group 1a: (n=55) Adults with a SRBD and COPD who are newly prescribed NIV treatment within the study period.~Group 1b: (n=55) Adults with a SRBD and COPD who are newly prescribed CPAP treatment within the study period.
- COPD controls not prescribed CPAP or NIV (Type: None): Group 2: COPD controls without a SRBD: (n=55) Adults with COPD who undergo sleep diagnostic testing and who are not recommended to start CPAP or NIV

Based on this trial design, predict the completion outcome and termination type (if applicable).